Thursday, August 21, 2014 9:00:26 PM
http://ldl.cardiosource.org/Science-And-Quality/Journal-Scan/2014/08/Triglycerides-and-Cardiovascular-Disease.aspx?pageview=microsite&w_nav=LN
Journal Scan Summary
Title: Triglycerides and Cardiovascular Disease
Date Posted: August 20, 2014
Authors: Nordestgaard BG, Varbo A.
Citation: Lancet 2014;384:626-635.
Related Resources
Journal Scan
LDL Cholesterol: Controversies and Future Therapeutic Directions
Journal Scan
HDL and Cardiovascular Disease
Perspective:
This article is the third in a series on lipids and cardiovascular disease (CVD). The following are 10 points to remember about triglycerides and CVD:
1. After the introduction of statins in the 1990s, clinical emphasis first focused on low-density lipoprotein (LDL) cholesterol-lowering, then on the potential for raising high-density lipoprotein (HDL) cholesterol, with less focus on lowering triglycerides. Furthermore, the observation that some adults with elevated triglycerides do not develop atherosclerosis led to skepticism regarding the association of triglycerides and CVD.
2. However, many randomized controlled trials of lipid-lowering therapies excluded patients with elevated triglycerides; thus, data on such patients and associated risk for CVD are lacking.
3. Current data (from observational and genetic studies) support the hypothesis that triglycerides can be measured in the nonfasting or fasting states, with concentrations of 2–10 mmol/L conferring increased risk of CVD, and concentrations >10 mmol/L conferring increased risk of acute pancreatitis and possibly CVD.
4. Meta-analyses examining triglycerides have observed that both fasting and nonfasting levels were associated with increased risk of coronary heart disease, even after adjustment for HDL cholesterol concentrations. In combined data from the Copenhagen City Heart Study and the Copenhagen General Population Study, increased risks for nonfasting triglycerides of 6.6 mmol/L versus 0.8 mmol/L, the age-adjusted and sex-adjusted hazard ratios were 5.1 (95% confidence interval, 3.5–7.2) for myocardial infarction, 3.2 (2.5–4.1) for ischemic heart disease, 3.2 (2.2–4.7) for ischemic stroke, and 2.2 (1.8–2.7) for all-cause mortality.
5. Genetic data also support the association of elevated triglycerides and CVD risk. A Mendelian randomization study with genetic variants in several candidate genes that affect the concentrations of remnant cholesterol or HDL cholesterol, or both, showed that an increase of 1 mmol/L in remnant cholesterol was associated with a 2.8-times increased risk of ischemic heart disease that was not attributable to low HDL cholesterol concentrations. Furthermore, genetically high levels of ruminant cholesterol have been associated with inflammatory markers, which were not observed in genetically elevated levels of LDL cholesterol.
6. In terms of treatment, for mild to moderately raised triglycerides, the secondary causes of raised triglycerides should be ruled out and treated.
7. Lifestyle modification is an important therapy and often includes weight loss and reducing alcohol intake.
8. Statin therapy or intensified statin therapy with a potent statin that lowers both triglyceride and LDL concentrations should be implemented; the effect of the statin on triglycerides depends on its capacity to lower LDL cholesterol and on baseline triglyceride concentrations. A fibrate can be added as needed for further triglyceride lowering. Fish oils and niacin can also reduce triglycerides; however, whether they also reduce CVD is unknown. For those with diabetes, improved glycemic control can lower triglyceride concentrations.
9. In the future, several new drugs with properties for lowering mild-to-moderately raised or very high concentrations of triglycerides are being developed or are already being tested in clinical trials, including some that are specifically aimed at reducing triglycerides. These drugs include n-3 fatty acids (fish oils), apolipoprotein C3 inhibitors, and LPL gene replacement therapy. Other new drugs in development have triglyceride-lowering properties among their functions; these drugs include proprotein convertase subtilisin/kexin type-9 inhibitors, microsomal triglyceride protein inhibitors, apolipoprotein B antisense therapies, cholesteryl ester transfer protein inhibitors, peroxisome proliferator-activated receptor agonists, and diacylglycerol O-acyltransferase-1 inhibitors; at present, the role of such drugs in treating raised triglycerides is unclear.
10. Although most novel therapies are only in the process of documenting safe triglyceride and remnant cholesterol-reducing properties, two large-scale, randomized, placebo-controlled n-3 fatty acid intervention trials of individuals with raised triglycerides have just been initiated: REDUCE-IT and STRENGTH. The REDUCE-IT trial aims to enroll 8,000 patients receiving a statin who either have CVD or are at high risk of CVD, and also have hypertriglyceridemia, with an estimated completion date in 2016. The STRENGTH trial aims to enroll 13,000 similar patients who also have low HDL cholesterol; the estimated completion date for this trial is 2019. Compared with previous studies with conventional fish oils, these two trials use purified, concentrated n-3 fatty acids.
Author(s):
Elizabeth A. Jackson, MD, F.A.C.C. (Disclosure)
Topic(s):
Prevention/Vascular, General Cardiology, Dyslipidemia, CardioMetabolic
Recent AMRN News
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM